Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.

Authors

Yunsik Choi
Sanghyuk Lee
Kapyoul Kim
Soo-Hyun Kim
Yeun-Jun Chung
Charles Lee, The Jackson LaboratoryFollow

Document Type

Article

Publication Date

8-7-2018

JAX Source

Exp Mol Med 2018 Aug 7; 50(8):99

Volume

50

Issue

8

First Page

99

Last Page

99

ISSN

2092-6413

PMID

30089794

DOI

https://doi.org/10.1038/s12276-018-0115-0

Grant

Ewha Womans University Research Grant

Abstract

Cancer immunotherapy is a promising way to eliminate tumor cells by using the patient's own immune system. Selecting the appropriate animal models to develop or validate preclinical immunotherapeutic trials is now an important aspect of many cancer research programs. Here we discuss the advantages and limitations of using genetically engineered immunodeficient mouse models, patient-derived xenografts (PDXs), and humanized mouse models for developing and testing immunotherapeutic strategies.

Comments

This open access article is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/)

Recommended Citation

Choi Y, Lee S, Kim K, Kim S, Chung Y, Lee C. Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice. Exp Mol Med 2018 Aug 7; 50(8):99